Navigation Links
Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohn's Disease and Ulcerative Colitis in the United States
Date:6/21/2013

new treatment options is well-recognized," said William J. Sandborn, M.D., chief, division of gastroenterology & professor of medicine, University of California San Diego School of Medicine. "In clinical development, vedolizumab has demonstrated the potential to be another possible treatment option for people with moderately to severely active CD and UC."

The BLA submission was supported by the Phase 3 clinical studies, GEMINI I, GEMINI II, GEMINI III and GEMINI LTS (Long-term Safety), which make up the GEMINI Studies™, a four-study clinical program to investigate the efficacy and safety of vedolizumab on clinical response and remission in moderately to severely active CD and UC patients. Enrolled patients had failed at least one conventional therapy, including corticosteroids, immunomodulators and/or a TNF-alpha antagonist. TNF-alpha antagonist failure patients included those with inadequate response (primary nonresponders), loss of response (secondary nonresponders) or those who were intolerant. Vedolizumab has been studied in 2,700 patients in nearly 40 countries, making it the largest Phase 3 clinical trial program conducted to date simultaneously evaluating both CD and UC.

GEMINI I was designed to assess the efficacy and safety of vedolizumab for inducing and maintaining clinical response and remission in patients with moderately to severely active UC in whom one prior therapy had failed. Key primary endpoints included clinical response at week six and clinical remission at week 52.

GEMINI II was designed to assess the efficacy and safety of vedolizumab for inducing and maintaining clinical response and remission in patients with moderately to severely active CD. Primary outcomes included the number of patients in clinical remission and enhanced clinical response at week six, and clinical remission at 52 weeks.

GEMINI III was designed to assess the efficacy and safety of vedolizumab
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
2. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
3. Takeda to Acquire Inviragen, Inc.
4. Takeda Responds to Verdict in Diabetes Drug Case
5. Takeda Launches New Subsidiary in Ecuador
6. Takeda lanza nueva subsidiaria en Ecuador
7. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
8. Takeda presenta la richiesta di autorizzazione allimmissione in commercio nellUnione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
9. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
10. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
11. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014  4WEB Medical announces the formal launch of ... osteotomy implants on the market today at this ... in Chicago .  The Osteotomy Truss ... needs with 74 size options included in one versatile ... only 15 to 18 implant sizes, which limited a ...
(Date:9/19/2014)... STATION, N.J. , Sept. 19, 2014 Merck (NYSE: ... United States and Canada , is ... Desafiando La Diabetes: Logra Tus Metas , an educational program ... their blood sugar -- a key treatment goal to help reduce ... United States are at a higher risk for developing ...
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
Breaking Medicine Technology:4WEB Medical Unveils 3D-Printed Osteotomy Truss System 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5David Dreyer Appointed to Diplomat Board of Directors 2
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... PR News at the Platinum PR and Top Places ... Hyatt in New York City. Camino received honorable mentions ... Shoestring Campaign” — for its work elevating Latina voices ... this incredible organization and be a part of its ...
(Date:9/19/2014)... Rockville Centre, NY (PRWEB) September 19, 2014 ... 17, the manufacturers of the embattled blood-thinner Xarelto, named ... County Court of Common Pleas, have moved the court ... the cases do not have sufficient connection with Philadelphia.* ... & Development, et al. (No. 140304328; Pa. Comm. Pls., ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Although there is ... benefits, most middle-aged and older adults in the ... exercise, according to new research. Less than ... recommendations set by the Department of Health and ... is essential for promoting health and fitness and ...
(Date:9/19/2014)... a leading anti-ageing clinic has called its HGH Therapy ... has grown tremendously across USA in the last decade with ... It has far reaching benefits for ageing men and women ... and active lifestyle even beyond their middle age. , ... MetroMD said, “HGH or Human Growth hormones are the building ...
(Date:9/19/2014)... --- Domestic violence occurs at least as frequently, ... compared to opposite-sex couples, according to a review ... , Previous studies, when analyzed together, indicate that ... of lesbian, gay and bisexual individuals. However, a ... paints an incomplete picture of the true landscape, ...
Breaking Medicine News(10 mins):Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:Domestic violence likely more frequent for same-sex couples 2
... NEW ORLEANS, LA (November 15, 2010) � Following ... Federation (FIP) Pharmaceutical Sciences World Congress (PSWC) in ... (AAPS) Annual Meeting and Exposition, President Danny D. ... awards commemorating their contributions to the pharmaceutical sciences: ...
... HealthDay Reporter , MONDAY, Nov. 15 (HealthDay News) -- Although ... death rates in public places such as restaurants, malls and ... the risk of death when used in hospitals, a new ... the type of heart rhythms associated with the heart attack, ...
... is widely believed to be caused by the gradual accumulation in ... Amyloid beta peptide is formed from a protein known as APP, ... a key area of study for the disease does not ... published in the Journal of Biological Chemistry , show that ...
... By Amanda Gardner HealthDay Reporter , SUNDAY, Nov. ... St. Paul saw a sharp decline in the number of ... elsewhere in the United States, experts say. The decline ... choosing to smoke in the first place, according to research ...
... salt each day as a teenager could reduce high ... to research presented at the American Heart Association,s Scientific ... projected the nationwide health effects of a 3-gram reduction ... boys and girls. Teenagers eat more salt each day ...
... Nov. 14 (HealthDay News) -- New research suggests that vitamin ... patients, even though it appears to double the risk for ... given that prior research has revealed that blacks are overall ... experience a stroke, compared with white patients. Blacks also have ...
Cached Medicine News:Health News:AAPS presents awards to exemplary researchers 2Health News:AAPS presents awards to exemplary researchers 3Health News:AAPS presents awards to exemplary researchers 4Health News:External Defibrillators Not Much Help in Hospitals 2Health News:External Defibrillators Not Much Help in Hospitals 3Health News:'Magic number' 695 opens up new areas for Alzheimer's research 2Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 2Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 3Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 4Health News:Less salt in teenagers' diet may improve heart health in adulthood 2Health News:Vitamin D Shortage Not Tied to Stroke Deaths in Blacks: Study 2
Poppen-Gelpi Laminectomy Retractor, self-retaining....
Valin Hemilaminectomy Retractor, self retaining with rack and pinion action....
Scoville-Haverfield Hemilaminectomy Retractor...
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment....
Medicine Products: